Matching articles for "neffy"
In Brief: Epinephrine 1 mg Nasal Spray (neffy)
The Medical Letter on Drugs and Therapeutics • April 28, 2025; (Issue 1727)
The FDA has approved a 1-mg epinephrine nasal spray
(neffy - ARS Pharma) for emergency treatment of
type 1 hypersensitivity reactions including anaphylaxis
in patients ≥4 years old who weigh 15 to...
The FDA has approved a 1-mg epinephrine nasal spray
(neffy - ARS Pharma) for emergency treatment of
type 1 hypersensitivity reactions including anaphylaxis
in patients ≥4 years old who weigh 15 to <30 kg. A
2-mg formulation of neffy was approved in 2024 for
use in patients who weigh ≥30 kg.
An Epinephrine Nasal Spray (neffy) for Anaphylaxis
The Medical Letter on Drugs and Therapeutics • October 14, 2024; (Issue 1713)
The FDA has approved an epinephrine nasal spray
(neffy – ARS Pharma) for emergency treatment
of type 1 hypersensitivity reactions including
anaphylaxis in patients who weigh ≥30 kg. It is
the first...
The FDA has approved an epinephrine nasal spray
(neffy – ARS Pharma) for emergency treatment
of type 1 hypersensitivity reactions including
anaphylaxis in patients who weigh ≥30 kg. It is
the first noninjectable epinephrine product to be
approved for this indication.